Spinal muscular atrophy: Clinical and genetic aspects, and therapeutic alternatives
Main Article Content
Keywords
Muscular Atrophy, Spinal, Rare Diseases, Genetic Therapy, Survival Motor Neuron Protein
Abstract
Abstract
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by a mutation in the SMN1 gene, located on chromosome 5q13. It is characterized primarily by neuronal degeneration due to a deficiency in producing full-length survival motor neuron protein (FL-SMN), which results in progressive muscle weakness with complications such as scoliosis, paralysis, and even death. This article reviews the clinical and genetic aspects of the disease, its diagnosis and classification, as well as therapeutic alternatives. In this context, it highlights the role of the molecular determination of the causal genetic variant and the copy number of the homologous SMN2 gene as the primary modifiers of the course of the disease, both for diagnosis and classification, as well as for therapeutic decision making. Recently, therapies focused on modifying the natural history of SMA by increasing FL-SMN protein production have been developed. Currently, 3 treatments are available: Spinraza (nusinersen), Zolgensma (onasemnogene abeparvovec), and Evrysdi (risdiplam). Studies performed with these drugs to confirm their safety and efficacy show favorable results; however, early diagnosis is decisive for the success of any of these therapeutic alternatives.
References
1. Ali HG, Ibrahim K, Elsaid MF, et al. Gene therapy for spinal muscular atrophy: the Qatari experience. Gene Ther. 2021;28(10-11):676-80. doi: 10.1038/s41434-021-00273-7
2. Farrar MA, Calotes-Castillo L, De Silva R, et al. Gene therapy-based strategies for spinal muscular atrophy-an Asia-Pacific perspective. Mol Cell Pediatr. 2023;10(1):17. doi: 10.1186/s40348-023-00171-5
3. Ando S, Osanai D, Takahashi K, et al. Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy. J Pharmacol Sci. 2020;144(4):204-11. doi: 10.1016/j.jphs.2020.09.001
4. Nishio H, Niba ETE, Saito T, et al. Clinical and Genetic Profiles of 5q- and Non-5q-Spinal Muscular Atrophy Diseases in Pediatric Patients. Genes (Basel). 2024;15(10): 1294 doi: 10.3390/genes15101294
5. Wang MJ, Kang L, Wang YZ, et al. Microglia in motor neuron disease: Signaling evidence from last 10 years. Dev Neurobiol. 2022;82(7-8):625-38. doi: 10.1002/dneu.22905
6. Basak S, Biswas N, Gill J, et al. Spinal Muscular Atrophy: Current Medications and Re-purposed Drugs. Cell Mol Neurobiol. 2024;44(1):75. doi: 10.1007/s10571-024-01511-3
7. Farrar MA, Mandarakas M, Briggs N, et al. Gestational Age at Birth and Clinical Manifestations of Spinal Muscular Atrophy. Neurology. 2025;105(2):e213799. doi: 10.1212/WNL.0000000000213799
8. Ishihara T, Koyama A, Atsuta N, et al. SMN2 gene copy number affects the incidence and prognosis of motor neuron diseases in Japan. BMC Med Genomics. 2024;17(1):263. doi: 10.1186/s12920-024-02026-y
9. Curry M, Cruz R, Belter L, et al. Awareness screening and referral patterns among pediatricians in the United States related to early clinical features of spinal muscular atrophy (SMA). BMC Pediatr. 2021;21(1):236. doi: 10.1186/s12887-021-02692-2
10. Angilletta I, Ferrante R, Giansante R, et al. Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies. Int J Mol Sci. 2023; 24(19):14873. doi: 10.3390/ijms241914873
11. Nishio H, Niba ETE, Saito T, et al. Clinical and Genetic Profiles of 5q- and Non-5q-Spinal Muscular Atrophy Diseases in Pediatric Patients. Genes (Basel). 2024;15(10):1294. doi: 10.3390/genes15101294
12. Nishio H, Niba ETE, Saito T, et al. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int J Mol Sci. 2023;24(15):11939. doi: 10.3390/ijms241511939
13. Lejman J, Panuciak K, Nowicka E, et al. Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives. Int J Mol Sci. 2023;24(2):1130. doi: 10.3390/ijms24021130
14. Ponomarev AS, Chulpanova DS, Yanygina LM, et al. Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape. Int J Mol Sci. 2023;24(18):13743. doi: 10.3390/ijms241813743
15. Hill SF, Meisler MH. Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders. Dev Neurosci. 2021;43(3-4):247-52. doi: 10.1159/000517686
16. Darras BT, Farrar MA, Mercuri E, et al. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials. CNS Drugs. 2019 ;33(9):919-32. doi: 10.1007/s40263-019-00656-w
17. Schorling DC, Pechmann A, Kirschner J. Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. J Neuromuscul Dis. 2020;7(1):1-13. doi: 10.3233/JND-190424
18. Crawford TO, Swoboda KJ, De Vivo DC, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023;68(2):157-70. doi: 10.1002/mus.27853
19. Thokala P, Stevenson M, Kumar VM, et al. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18:41. doi: 10.1186/s12962-020-00234-8
20. Park JM, Min YS, Park D, et al. Effect of Nusinersen in a late onset spinal muscular atrophy patient for 14 months: A case report. Medicine (Baltimore). 2021;100(1):e24236. doi: 10.1097/MD.0000000000024236
21. Ogbonmide T, Rathore R, Rangrej SB, et al. Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma). Cureus. 2023;15(3):e36197. doi: 10.7759/cureus.36197
22. Day JW, Howell K, Place A, et al. Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr. 2022;22(1):632. doi: 10.1186/s12887-022-03671-x
23. Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284-93. doi: 10.1016/S1474-4422(21)00001-6
24. Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021;78(7):834-41. doi: 10.1001/jamaneurol.2021.1272
25. Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381-9. doi: 10.1038/s41591-022-01866-4
26. Chong LC, Gandhi G, Lee JM, et al. Drug Discovery of Spinal Muscular Atrophy (SMA) from the Computational Perspective: A Comprehensive Review. Int J Mol Sci. 2021;22(16):8962. doi: 10.3390/ijms22168962
27. Masson R, Mazurkiewicz-Beldzinska M, Rose K, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110-9. doi: 10.1016/S1474-4422(22)00339-8
28. Oskoui M, Day JW, Deconinck N, et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270(5):2531-46. doi: 10.1007/s00415-023-11560-1
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.